Corpus Intelligence IC Memo — MOUNT SINAI HEALTH SYSTEM-BETH ISRAE 2026-04-26 06:40 UTC
IC Memo — MOUNT SINAI HEALTH SYSTEM-BETH ISRAE
Investment Committee Memorandum | NY | 437 beds | Grade C | EBITDA uplift $59.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MOUNT SINAI HEALTH SYSTEM-BETH ISRAE

CCN 330169 | NEW YORK, NY | 437 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MOUNT SINAI HEALTH SYSTEM-BETH ISRAE is a 437-bed suburban community hospital in NEW YORK, NY with $801.8M in net patient revenue and a -33.7% operating margin. The hospital serves a payer mix of 30.3% Medicare, 7.0% Medicaid, and 62.6% commercial.

Thesis: Undervalued. Our ML models identify $59.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -33.7% to -26.3% (+736bps).

Net Revenue HCRIS$801.8M
Current EBITDA COMPUTED$-270.1M
Operating Margin COMPUTED-33.7%
Occupancy HCRIS77.6%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS20.8%
Distress Probability ML41.8%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
64
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -33.7% places it below the state median. Among 64 size-comparable peers (218-874 beds), the median margin is -17.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (218-874), prioritizing same-state peers. 64 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MOUNT SINAI HEALTH SYSTEM-BETH (Target)NY437$801.8M-33.7%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
NORTH SHORE UNIVERSITY HOSPITANY782$2.27B-50.0%
STONY BROOK UNIVERSITY HOSPITANY725$1.90B-4.9%
WESTCHESTER MEDICAL CENTERNY696$1.63B2.6%
UNIVERSITY HOSPITAL AT SYRACUSNY625$1.33B-17.2%
LENOX HILL HOSPITALNY415$1.32B-35.1%
BELLEVUE HOSPITAL CENTERNY527$1.31B-17.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $59.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$16.8M+210bp18mo
Cost to Collect4.5%2.5%$16.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$15.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$9.8M+122bp9mo
Clean Claim Rate88.0%96.0%$513K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$16.8M
Cost to Collect
$16.0M
Denial Rate Reduction
$15.9M
A/R Days Reduction
$9.8M
Clean Claim Rate
$513K
Total EBITDA Uplift$59.0M
Current EBITDA$-270.1M
+ RCM Uplift+$59.0M
Pro Forma EBITDA$-211.1M
Current Margin-33.7%
Pro Forma Margin-26.3%
WC Released (1x)$30.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-415.6M$-1.19B0.00x-100.0%
Base (11x exit)10.0x11.0x$-415.6M$-1.45B0.00x-100.0%
Bull Case9.0x11.0x$-374.0M$-1.39B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-374.0M$-1.62B0.00x-100.0%
Bear Case11.0x10.0x$-457.1M$-1.35B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-457.1M$-1.64B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 64 hospitals with 218-874 beds
  • Same-state prioritization (n=65)
  • Comp margins: P25=-23.1% / P50=-17.3% / P75=-9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.